aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
aTyr Pharma (LIFE) Tops Q3 EPS by 6c
November 12, 2020 4:38 PM ESTaTyr Pharma (NASDAQ: LIFE) reported Q3 EPS of ($0.68), $0.06 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $148 thousand versus the consensus estimate of $100 thousand.
Throughout the third quarter, we remained focused on our clinical program for our lead therapeutic candidate, ATYR1923. We now... More
